Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 20, 2026 10:00 ET | Source: Adaptin Bio

Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell...
January 15, 2026 09:00 ET | Source: Adaptin Bio

Adaptin Bio to Present at the 2026 Sequire Investor Summit in Puerto Rico

CHARLOTTE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therapies with targeted delivery to...
April 07, 2025 12:25 ET | Source: Adaptin Bio

Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement

Funding expected to support first clinical trial of APTN-101 for the treatment of glioblastoma CHARLOTTE, N.C., April 07, 2025 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (“Adaptin” or the “Company”), a...